Could you help your patients step into FREEDOM?
The FREEDOM-3 clinical trial is a phase 1/2a, single-arm, multi-center, open-label trial that will evaluate the safety, tolerability, and efficacy of an allogeneic hematopoietic stem cell transplant with an investigational cell therapy called FCR001 in people with rapidly progressing dcSSc and who are at risk for organ failure.
To learn more about the FREEDOM-3 clinical trial please visit ClinicalTrials.gov: NCT05098145
*Recipients and donors may be related (e.g., a biological child, sibling, cousin), but they do not have to be. All donors must be willing to donate peripheral blood stem cells and meet other eligibility criteria to participate.
Both recipients and donors will undergo human leukocyte antigen (HLA) testing to confirm that they are a compatible match for the stem cell transplant. The study team will discuss this with potential participants in more detail.
Participants may experience side effects and/or health complications from the medicines,
investigational cell therapy, and/or assessments and procedures.